Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acorda Therapeutics (NQ: ACOR )

14.57 -0.67 (-4.40%)
Streaming Delayed Price Updated: 3:56 PM EDT, Sep 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,276
Open 15.01
Bid (Size) 13.28 (1)
Ask (Size) 17.00 (3)
Prev. Close 15.24
Today's Range 14.06 - 15.03
52wk Range 0.2611 - 18.20
Shares Outstanding 1,242,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga

Performance

YTD
+1756.05%
+1756.05%
1 Month
+9.71%
+9.71%
3 Month
+15.73%
+15.73%
6 Month
+2328.33%
+2328.33%
1 Year
+4906.87%
+4906.87%

More News

Read More
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
From Acorda Therapeutics
Via Business Wire
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
From Acorda Therapeutics
Via Business Wire
Tom Burns Elected to the Acorda Therapeutics Board of Directors
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Acorda Therapeutics
Via Business Wire
Why Semtech Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
From Acorda Therapeutics
Via Business Wire
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Via Talk Markets
Acorda Therapeutics Reports First Quarter 2023 Financial Results
From Acorda Therapeutics
Via Business Wire
3 Penny Stocks to Avoid as Interest Rates Rise in 2023
Via InvestorPlace
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
From Acorda Therapeutics
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
From Acorda Therapeutics
Via Business Wire
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
From Acorda Therapeutics
Via Business Wire
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month
From Acorda Therapeutics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.